Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973–2011

Deadmond, Melissa A.; Smith-Gagen, Julie

doi:10.1007/s00432-015-1983-5

Cited by 45 publications

(38 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The annual incidence of PV and ET was similar 1.5–1.6/100 000 persons while the incidence of PMF was as expected lower, around 0.5/100 000 persons. The incidence of PV and PMF was higher in men and ET was more common in women, which is line with earlier reports . The incidence of PV remained stable over time while there was an increase in the incidence of ET and PMF and a simultaneous decrease in the incidence of MPN‐U.…”

Section: Discussionsupporting

confidence: 91%

“…Several investigators have assessed the incidence of MPNs in different parts of the world. The incidence of all subtypes of MPNs combined, ranges from 2–3/100 000 person‐years, occasionally up to 4–4.5/100 000 person‐years in previous studies . As for the incidence of the different MPN subtypes, a recent meta‐analysis revealed pooled figures of 0.84 PV cases, 1.03 ET cases and 0.47 PMF cases /100 000 person‐years .…”

Section: Discussionmentioning

confidence: 94%

See 1 more Smart Citation

Incidence of myeloproliferative neoplasms – trends by subgroup and age in a population‐based study in Sweden

et al. 2020

View full text Add to dashboard Cite

Background The reported incidence of Philadelphia‐negative myeloproliferative neoplasms (MPNs) differs substantially between previous reports, likely due to true regional differences in incidence and/or variations in the quality and coverage of the cancer registers. Objective We therefore assessed MPN incidence in Sweden during recent years using prospectively collected information captured in Swedish health registers. Methods Patients with MPNs were identified through the Swedish Cancer Register and Swedish Blood Cancer Register between 2000 and 2014. Information on the Swedish population was obtained from the Human Mortality Database. Crude and age‐standardized incidence rates of MPNs with 95% confidence intervals (CIs) were calculated. Results A total of 6281 MPN cases were reported to the Swedish Cancer Register and Swedish Blood Cancer Register during 2000–2014. The age‐standardized, to the Swedish population in 2000, incidence for all MPNs was 4.45 (95% confidence interval [CI] 4.34–4.56)/100 000 person‐years. The age‐standardized incidence for polycythemia vera was 1.48 (1.42–1.54), for essential thrombocythemia 1.60 (1.53–1.66) and for primary myelofibrosis 0.52 (0.48–0.56)/100 000 person‐years, respectively. The incidence rate of MPNs was substantially higher in the older compared to the younger age groups. The incidence increased during the study period, likely to do better reporting and increasing age of the general population. Conclusion The reported MPN incidences in our study, which were in the higher interval of previously published studies, are likely more accurate compared to previous reports due to the population‐based setting and high level of coverage in the Swedish Cancer and Blood Cancer Registers.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 94%

Incidence of myeloproliferative neoplasms – trends by subgroup and age in a population‐based study in Sweden

et al. 2020

View full text Add to dashboard Cite

show abstract

“…[5] Since 2005, when screening of JAK2 mutation has begun, it was reported that the rates of correct ET diagnosis have increased by 31% and the rates of correct PV diagnosis have decreased by 21%. [10] In our study, the frequency of the JAK2 V617F mutation has been found 73% in PV patients, and 61% in ET, as those rates were found to be lower in PV patients compared to reported rates. [11] JAK2 mutation has been found in five of nine cases (55%) with PMF.…”

Section: Discussionsupporting

confidence: 42%

Janus kinase 2 mutations in cases with BCR-ABL-negative chronic myeloproliferative disorders from Turkey

2017

View full text Add to dashboard Cite

Objective:We aimed to investigate the frequency of Janus kinase 2 (JAK2) mutations in cases with chronic myeloproliferative disorders (CMDs), and the relationship between the presence of JAK2 mutation and leukocytosis and splenomegaly, retrospectively.Materials and Methods:Patients, who were diagnosed with BCR-ABL-negative CMDs according to diagnosis criteria of the World Health Organization and followed up at the hematology clinic between 2013 and 2015, were investigated in terms of the frequency of JAK2 mutation in cases with CMDs, and the relationship between the presence of JAK2 mutation and leukocytosis and splenomegaly, retrospectively.Results:In total, 100 patients, who were diagnosed with BCR-ABL-negative CMDs, were evaluated retrospectively. The mean age of the patients with JAK2 positivity was significantly higher compared to patients with negative. JAK2-positivity rates in the age groups were significantly different. Gender, diagnosis, splenomegaly, and leukocytosis were not statistically different for JAK2 positivity between the groups.Conclusion:JAK2 V617F mutation is more commonly seen in older age as a risk for complications related to CDMS. Splenomegaly and leukocytosis are not associated with JAK2 V617F mutation.

show abstract

“…In 2010, the prevalence of ET, PV and MF was 134,000, 148,000 and 13,000, respectively, in the United States(2). PV and MF are more common in males, while there is a small preponderance for females in ET(3). Risk factors for the development of MPNs include white race and older age(4).…”

Section: Introductionmentioning

confidence: 99%

New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape

Patel

Vellore

Deininger

2016

Clinical Cancer Research

View full text Add to dashboard Cite

The classical BCR-ABL1-negative myeloproliferative neoplasms (MPNs) include essential thrombocythemia (ET), polycythemia vera (PV) and myelofibrosis (MF). While these clonal disorders share certain clinical and genetic features, MF in particular is distinct for its complex mutational landscape, severe disease phenotype and poor prognosis. The genetic complexity inherent to MF has made this disease extremely challenging to treat. Pharmacologic JAK inhibition has proven to be a transformative therapy in MPNs, alleviating symptom burden and improving survival, but has been hampered by off-target toxicities and, as monotherapy, has shown limited effects on mutant allele burden. In this review, we discuss the genetic heterogeneity contributing to the pathogenesis of MPNs, focusing on novel driver and epigenetic mutations and how they relate to combination therapeutic strategies. We discuss results from ongoing studies of new JAK inhibitors and report on new drugs and drug combinations that have demonstrated success in early preclinical and clinical trials, including Type II JAK inhibitors, anti-fibrotic agents and telomerase inhibitors.

show abstract

Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973–2011

Cited by 45 publications

References 27 publications

Incidence of myeloproliferative neoplasms – trends by subgroup and age in a population‐based study in Sweden

Incidence of myeloproliferative neoplasms – trends by subgroup and age in a population‐based study in Sweden

Janus kinase 2 mutations in cases with BCR-ABL-negative chronic myeloproliferative disorders from Turkey

New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape

Contact Info

Product

Resources

About